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New IL-15 receptor-a splicing variants
identified in intestinal epithelial Caco-2
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Abstract
IL-15 is a pleiotropic cytokine related to IL-2 which acts at a broader level than its counterpart. It is presented through its
specific high-affinity receptor, IL-15Ra. Both cytokine and receptor are tightly regulated at multiple levels and are widely
distributed. Thus, deregulation of their expression leads to an inflammatory immune response. Variants of splicing of
IL-15Ra have been described in immune and barrier cells; however, their presence has not been focused on intestinal
epithelial cells. In this study, we describe five new alternative variants of splicing of IL-15Ra in Caco-2 cells. Four of them
were expressed into proteins inside Caco-2 cells, but these were unable to bind IL-15 or to follow the secretory
pathway. However, the expression of mRNA itself might be relevant to diseases such as celiac disease, inflammatory
bowel disease or colorectal cancer.
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Introduction
IL-15 is a pleiotropic cytokine with multiple eﬀects in
both innate and adaptive immune cells.1 It was dis-
covered in 1994 as a result of its ability to stimulate
proliferation of T cells in a similar way to IL-2.2,3
Altogether, IL-2, IL-7, IL-15, IL-21 and other growth
factors of cytokine family type I share a common recep-
tor, IL-R2gc (CD132). IL-2 and IL-15 also share the
IL-2Rb subunit (CD122), but diﬀer in their speciﬁc
receptor, IL-2Ra (CD25) or IL-15Ra (CD215), respect-
ively.1 It is the expression pattern of IL-15 and IL-15Ra
and its aﬃnity that make IL-15 act at a broader level
than IL-2 in the organism.
The expression of IL-15 is deeply regulated at ﬁve
diﬀerent levels: (1) the IL-15 promoter, which contains
transcription factor binding sites for IFN and IL-6 (2)
the 5’ UTR region, with 12 translation initiation sites
(AUG), (3) its signal peptide and (4) its carboxyl term-
inal sequences, that limit its translation and secretion.1,7
These checkpoints can limit IL-15 production up to 250
times.1 Although IL-15 mRNA is constitutively
expressed by many cells and tissues, the protein is
detected only on monocytes, dendritic cells, epithelial
cells and ﬁbroblasts.1 The expression pattern of this
cytokine could be aﬀected by the expression of
IL-15Ra, as both proteins interact in the endoplasmic
reticulum and are secreted together.4 This mechanism is
not shared by other cytokines and allows IL-15 to
remain attached to the membrane of IL-15-expressing
cells.4 As a consequence, IL-15 can be trans-presented
to nearby cells expressing the moderate aﬃnity recep-
tor, IL-2Rb/gc, or the high-aﬃnity trimeric receptor
formed by IL-2Rb/gc and the speciﬁc IL-15Ra sub-
unit.5 While signaling to nearby cells, a signal can be
also processed within the IL-15-presenting cell, which is
identiﬁed as reverse presentation.6–8 Other minor action
forms are the intracrine presentation, which takes place
in the nucleus when IL-15 is expressed as an alternative
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isoform containing a short-signal peptide, then acting
as suppressor,9 and the paracrine presentation, which
takes place when the membrane IL-15/IL-15Ra com-
plex is processed by proteolysis and released to the
extracellular medium.4
However, the gene encoding IL-15Ra, IL15RA, is
located on chromosome 10p15.1 and includes seven
exons. Each exon encodes for diﬀerent protein domains:
(1) signal peptide, (2) sushi domain, (3) linker, (4-5) pro-
line and threonine-rich domains, (6) transmembrane
domain and (7) a small cytoplasmic domain with no
kinase activity.10 The latter domain, although not essen-
tial for trans-presentation,11 plays a regulatory role in
the development of IL-17-producing gdT cells,12 as
well as acting as a T-cell activation adjuvant for HIV-1
DNA vaccination.13 The isoforms which do not contain
the sushi domain (exon 2) are unable to bind IL-15 and
unable to localize in the cellular nucleus.10
As both IL-15 and IL-15Ra are widely distributed,
the deregulation of their mRNA and protein expression
leads to an inﬂammatory immune response.14 Besides,
epigenetics could participate in inducing this deregula-
tion as it has already been shown that IL-15Ra expres-
sion can be regulated through DNA methylation, and
thus diﬀerently expressed in a tissue-speciﬁc way.15
Some pathologies where the IL-15/IL-15Ra system is
deregulated include celiac disease, inﬂammatory bowel
disease (IBD) or colorectal cancer.16
The present work is focused on the intestinal epithe-
lial cells as they are at the front line, with contact with
dietary components and microbiota within the gut, and
they are also capable of signaling to immune cells.17 In
addition, the regulation of IL-15Ra was studied, par-
ticularly on the description of the IL-15Ra splice vari-
ants as they speciﬁcally vary depending on the tissue.18
The aim of this work was to describe variants of
splicing of IL-15Ra expressed in human intestinal
epithelial cells, using Caco-2 cells as a model, and to
identify those variants with the ability of binding IL-15
and following the secretory pathway, as well as to
determine if any of these variants were regulated by
methylation of DNA.
Material and methods
The Caco-2 cell line
The Caco-2 cell line, passages 22–28, collection number
86010202 (p44; Health Protection Agency, London,
UK) was grown in DMEM medium (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) supplemented with
15% of FBS (Gibco, Carlsbad, CA, USA), 1% of 2-
[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid,
HEPES (Gibco), 1% non-essential amino acids
(Thermo Fisher Scientiﬁc) and 1% penicillin-strepto-
mycin (Sigma-Aldrich, St. Louis, MO, USA) in
10mm plates (BD, Franklin Lakes, NJ, USA) at 37C
and 5% CO2. The medium was replaced every other
day; after 80% conﬂuency, cells were detached with
TrypLETM Express (Life Technologies, Carlsbad, CA,
USA) and seeded in a new culture dish. Unstimulated
Caco-2 cells were harvested for RNA extraction.
For inhibition of de novo DNA methylation, Caco-2
cells were grown as previously described in presence of
0.1, 1 and 10 mM of 5-aza-2’-deoxycytidine (AZA;
Sigma-Aldrich) for 24 or 48 h. The experiments were
performed in triplicate.
Patient samples and isolation of epithelial cells
Biopsy specimens from healthy individuals were
obtained from the Servicio de Aparato Digestivo
(n¼ 7), Hospital Clı´nico Universitario of Valladolid
(Spain); ﬁve of them were derived from colon (C) and
the remaining from duodenum (D). Written informed
consent was obtained from all subjects and the study
was approved by the ethics committee.
Biopsy samples were submerged in physiological
solution and immediately processed. A ﬁrst isolation
of the epithelial layer was performed by incubating
samples in RPMI 1640 medium (Lonza, Basel,
Switzerland) supplemented with 10% FBS (Gibco),
1% penicillin-streptomycin (Sigma-Aldrich), 1%
l-glutamine (Sigma-Aldrich), 1mM EDTA (Sigma-
Aldrich) and 1mM DTT (Sigma-Aldrich) for 1 h with
moderate rotation at 37C. Afterwards, the epithelial
layer was obtained (centrifugation at 700 g, 10min)
and cells were labeled with EpCAM-FITC and CD45-
PE-Cy7 for 30min at 4C (both from BD). Epithelial
cells were isolated in a FACS Aria Sorter (BD), select-
ing the EpCAM+ CD45– cells.
Cloning
Total RNA was extracted from unstimulated Caco-2
cells with an RNeasy mini kit following the manufac-
turer’s instructions (QIAGEN, Hilden, Germany).
Quantiﬁcation was carried out in a NanoDrop ND-
1000 (Thermo Fischer Scientiﬁc) and retrotranscription
was performed with a High Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientiﬁc). cDNA
was ampliﬁed with GoTaq Green Master Mix
(Promega, Fitchburg, WI, USA), using primers targeting
the start and stop codons—when possible—of the
coding full-length IL-15Ra sequences described in
NCBI database (variant 1, NM_002189.3; variant 2,
NM_172200.2; variant 3, NM_001243539.1 and variant
4, NM_001256765.1). Forward primer for variants 1 and
2: 5’–AGTCCAGCGGTGTCCTGTG –3’; forward pri-
mer for variant 3: 5’–ATGTCCGTGGAACACGC
AGA–3’; forward primer for variant 4: 5’–AAGCG
AAAGCGAATGCGACTGG–3’; common reverse
primer for all four variants: 5’–TCATAGGTG
GTGAGAGCAGTTTTC–3’. The PCR products were
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obtained after electrophoresis and the DNA was
extracted with QIAquick Gel Extraction Kit
(QIAGEN). Each product was cloned into the
pCR2.1-TOPO vector following the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA), and gen-
erated in chemically competent Escherichia coli DH5a
cells cultured in presence of 100mg/ml of ampicillin
(Sigma-Aldrich). The positive colonies were tested by
PCR and digested with restriction enzymes BamHI
and XhoI following the manufacturer’s instructions
(both from New England BioLabs, Ipswich, MA,
USA). DNA from positive colonies was extracted with
QIAprep Spin Miniprep kit (QIAGEN), sequenced and
analyzed. The sequences were subcloned into the
pEGFP-N1 vector (Clontech Laboratories, Mountain
View, CA, USA) for transfection of Caco-2 cells. New
primers were designed to ensure the elimination of unde-
sired sequences of pCR2.1-TOPO, to facilitate a subse-
quent enzymatic digestion and to improve their
expression: Forward primer V1-2: 5’- ATTCTCG
AGCACCATGGCCCCGCGGCGG- 3’; forward
primer V3-1: 5’- ATTCTCGAGCACCATGCT
ACCTCAAGTCAAGGC-3’; forward primer V3-2: 5’-
ATTCTCGAGCACCATGCCTTCAAAATCACCTT
CC- 3’; forward primer V3-3: 5’- ATTCTCGAGC
ACCATGTCCGTGGAACACGCAG-3’; common
reverse for all the variants: 5’- ATTCCTAGG
GCATCCACCACTCTCGTCAAAAG- 3’.
Transfection of Caco-2 cells
Caco-2 cells were transfected with the IL-15Ra splicing
variants by using Lipofectamine LTX and Plus Reagent
(Life Technologies). Brieﬂy, 1 mg pEGFP-N1 vector
was incubated for 15min at room temperature (25C)
with 200 ml of medium without serum or antibiotics and
1 ml Plus Reagent. Lipofectamine LTX reagent was
added (3ml) and incubated for 25min at room tempera-
ture. Finally, the transfection mix was added to 100,000
Caco-2 cells in suspension. Cells were cultured in 24-
well plates (BD) and, after incubation for 18 h; FBS
was added to a ﬁnal concentration of 15%. Geneticin
(1mg/ml; Sigma-Aldrich) was added after 40 h. Cells
were harvested after evaluation under an inverted ﬂuor-
escence microscope (48–72 h after transfection). The
transfection eﬃciency was 40–44% (Figure S1) as mea-
sured by ﬂow cytometry on transfected cells by using
the empty pEGFP-N1 vector. Empty pEGFP-N1
vector was used as a control.
Immunofluorescence
Transfected Caco-2 cells were directly cultured in slides
in four-well plates (Thermo Fisher Scientiﬁc).
Afterwards, cells were washed twice with PBS and
ﬁxed with 4% paraformaldehyde for 30min at room
temperature. Autoﬂuorescence was eliminated with
0.1mM ammonium chloride for 10min (all from
Sigma-Aldrich). Blockage and permeabilization were
performed with 3% FBS and 0.25% Triton X-100
(BioRad, Hercules, CA, USA) for 30min. The primary
Ab was incubated overnight at 4C, and the secondary
Ab was incubated for 1 h together with (DAPI) (Sigma-
Aldrich). The following primary Abs were used: poly-
clonal rabbit anti-human calnexin, monoclonal mouse
anti-human coatomer protein B (COPB) and poly-
clonal rabbit anti-human lysosomal membrane-
associated protein 1 (LAMP-1) (all of them from
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The corresponding secondary Abs were labeled with
Alexa Fluor 594 (Life Technologies). The samples
were analyzed in a Leica sp5 confocal microscope
(Leica Microsystems GmbH, Wetzlar, Germany).
Assays were performed in duplicate.
Western blot
Proteins from transfected Caco-2 cells were obtained
with RIPA buﬀer following the manufacturer’s instruc-
tions (Sigma-Aldrich). Electrophoresis was performed
in a 15% acrylamide/bis-acrylamide gel (BioRad) and
proteins were transferred to a PVDF membrane in wet
conditions. Blockage was performed with 4% FBS in
0.1% Tween20 Tris-borate–EDTA, TBE solution (all
from Thermo Fisher Scientiﬁc). The primary Ab used
was a polyclonal rabbit anti-EGFP (Thermo Fisher
Scientiﬁc). The corresponding secondary Ab was
labeled with HRP (Dako, Santa Clara, CA, USA).
Supersignal Western Blot Substrate (Thermo Fisher
Scientiﬁc) and VersaDoc equipment (BioRad) were
used to obtain the results. The assay was performed
in duplicate.
Quantitative and semi-quantitative PCR
Total RNA was extracted from Caco-2 cells or isolated
epithelial cells from healthy intestinal biopsies with an
RNeasy mini kit following the manufacturer’s instruc-
tions (QIAGEN). Quantiﬁcation was carried out in a
NanoDrop ND-1000 (Thermo Fischer Scientiﬁc) and
retrotranscription was performed with a High
Capacity cDNA Reverse Transcription Kit (Thermo
Fisher Scientiﬁc).
cDNA from Caco-2 cells was ampliﬁed with iTaq
Universal SYBR Green Supermix (BioRad) or GoTaq
Green Master Mix (Promega), for quantitative or semi-
quantitative PCR, respectively. The speciﬁc primers
for the diﬀerent variants of IL-15Ra are described in
Table 1.
Quantitative analysis was carried out in a LightCycler
480 (Roche, Rotkreuz, Switzerland) using the relative
quantiﬁcation 2 -Ct method.19 Isoforms whose
sequence was embedded in the sequence of longer
isoforms were quantiﬁed using a semi-quantitative
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method: the density of the bands in an agarose gel was
calculated with Quantity One v4.6.6 (BioRad). In both
cases, GADPH was used as a reference (Table 1). Each
sample was analyzed in duplicate.
cDNA from isolated epithelial cells was ampliﬁed by
using GoTaq Green Master Mix (Promega) for quali-
tative PCR. The speciﬁc primers for the diﬀerent vari-
ants of IL-15Ra are described in Table 1.
Statistical analysis
Quantitative and semi-quantitative PCR data were ana-
lyzed with the non-parametric Mann–Whitney test,
considering P< 0.05 as statistically signiﬁcant.
Analysis was performed in the SPSS software v15.0
(IBM, Armonk, NY, USA).
Results
Identification of IL-15R variants
The coding DNA sequence of human IL-15Ra was
ampliﬁed with a set of primers targeting the start and
stop codons, when possible. From the four diﬀerent
coding variants described in the NCBI database, amp-
liﬁcation was obtained for variants 1, 2 and 3
(NM_002189.3, NM_172200.2 and NM_001243539.1,
respectively), but not for variant 4 (NM_001256765.1)
(Figure 1).
The shortest ampliﬁcation product obtained in the
ampliﬁcation of variant 3 corresponded to a non-
speciﬁc ampliﬁcation. The remaining products corres-
ponded to IL-15Ra isoforms (Figure 1). Identiﬁcation
of the isoforms was denoted by the ampliﬁcation reac-
tion and the number of bp of the coding sequence: V1-
2, 276 bp, and V1-2, 510 bp, for the isoforms derived
from the ampliﬁcation reaction of variants 1 and 2; V3,
130 bp, 348 bp and 498 bp for the isoforms derived
from the ampliﬁcation reaction of variant 3 (Figure 2,
Table 2).
The isoforms derived from sequences 1 and 2
are composed of exons 1, 6 and 7 (276 bp) and exons
1, 4, 5, 6 and 7 (510 bp). The isoforms derived from
sequence 3 are composed by exon 6 and 7 (130 bp);
exons 4 to 7 (348 bp) and exon 2, part of exon 4 and
exons 5 to 7 (498 bp) (Figure 2). The predicted proteins
of these isoforms have diﬀerent characteristics; they
vary from alkalinic to acidic proteins, and their molecu-
lar mass ranges from 3.06 to 17.98 kDa (Table 2).
Table 1. Sequence of the primers used for quantitative PCR.
Gene Forward primers (5’!3’) Reverse primers (5’!3’)
GADPH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
V1 GGCGACGCGGGGCATCAC GTGGCGCTGGCCTTTGGTGAA
V2 GGCGACGCGGGGCATCAC TGAAGCTGCGGGCTTAATGCATTTG
V1-2 276 bp GACGCGGGTGGCTATCT TAGGTGGTGAGAGCAGTTTTC
V1-2 510 bp CGGGAGCCCGCAGCTTC CAGCAGGACAGTGGACGTGG
V3 GCCGCAGAGAGGGCTGGAGAG GTGGCGCTGGCCTTTGGTGAA
V3 130 bpa ATGTCCGTGGAACACGCAGA TCATAGGTGGTGAGAGCAGTTTTC
V3 348 bpa ATGTCCGTGGAACACGCAGA TCATAGGTGGTGAGAGCAGTTTTC
V3 498 bp TGCATTAGAACCACAGAGATAAGCAGT CAGCAGGACAGTGGACGTGG
V4 CCCAGTGCCACCACCATCGG GTGGCGCTGGCCTTTGGTGAA
Primers were designed by using Primer Express 3.0 (Applied Biosystems). V: variant.
aNon-specific primers: these amplify all IL-15Ra isoforms of variant 3 and were analyzed semi-quantitatively (densitometry of bands in
agarose gel was analyzed instead of using quatitative PCR).
bp
V1-2 V3 V4
650
500
300
Figure 1. Products of amplification of the coding transcripts of
IL-15Ra from Caco-2 RNA. The lane on the left corresponds to
the molecular mass marker. Products of amplification were
obtained for variants 1, 2 and 3, in a range from approximately
300 to 650 bp.
V: variant.
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It is known that exon 2 codiﬁes for the sushi domain,
which is responsible for binding to IL-15. Of the iden-
tiﬁed isoforms, there is only one with the ability of
competing for IL-15, this is the isoform containing
498 bp derived from variant 3 (Figures 2 and 3).
Although this isoform does not contain the whole
sushi domain, as it does not have the ﬁrst amino acid
sequence of exon 2, it contains the two amino acids
involved in IL-15 binding (Figure 3).
Protein expression of IL-15R isoforms
and subcellular localization
To determine if variants of IL-15Ra were capable of
being translated into proteins, a sub-cloning step was
performed. Fused isoforms of IL-15Ra with the
enhanced green ﬂuorescent protein (EGFP) were
easily detected in an inverted ﬂuorescence microscope
after Caco-2 cell transfection (48–72 h). Western blot
analysis was then performed against EGFP. The only
isoform that was not translated into protein was V3
498 bp (Figure 4), meaning that none of the expressed
isoforms will be able to bind IL-15.
As observed in Figure 4, the remaining samples were
detected in the corresponding molecular mass for the
EGFP protein alone and, besides, an extra band which
corresponds to the molecular mass of the transfected
isoform together with EGFP: for the isoform contain-
ing 276 bp, a band of 42.6 kDa was detected; for the
isoform containing 510 bp, a band of 50.4 kDa; and
for the isoform containing 348 bp, a band of 44.8 kDa
(Figure 4). Moreover, the detection of the isoform con-
taining 130 bp resulted in a band of 35.8 kDa; that is,
the predicted protein which starts in its second initi-
ation codon (Figure 4 and Table 2). The subcellular
localization of the diﬀerent isoforms was also studied
by immunoﬂuorescence. All the isoforms showed a gen-
eral cytoplasmic distribution, besides granular accumu-
lation (Figure 5).
When the localization in diﬀerent organelles was
considered, all the isoforms partially co-localize
within the endoplasmic reticulum. This observation is
clearer for the isoforms containing 276 and the 348 bp,
although a slight co-localization is also appreciated in
transfected cells with pEGFP alone (Figure 5, calnexin
panels). However, no co-localization was observed with
Golgi apparatus (COPB) or lysosomal proteins
(LAMP-1) (Figure 5).
Regulation of IL-15R isoforms by methylation
of DNA
As expression of IL-15Ra can be speciﬁcally regulated
through methylation of DNA in diﬀerent tissues,15 its
expression was assessed in presence of an inhibitor of
DNA methyltransferase. To that end, Caco-2 cells were
cultured with 0.1, 1 and 10 mM AZA to inhibit the de
novo methylation of DNA. Afterwards, speciﬁc quanti-
tative PCR was performed for each isoform (Table 1).
Isoforms whose sequence was embedded in the
sequence of longer isoforms were quantiﬁed from the
density of the agarose gel bands (Figure 1). As results
after 24 h in the presence of AZA did not last long
enough to have a consistent eﬀect on cells (data not
shown), stimulation was performed after 48 h.
The absence of DNA methylation signiﬁcantly
increased the expression of all the IL-15Ra splicing
variants in the presence of AZA (Figure 6). The two
isoforms derived from variant 3, which were evaluated
semi-quantitatively, did not show the same variation;
and even their expression was signiﬁcantly decreased
(Figure 6).
V1-2 276 bp
V1-2 510 bp
V3 130 bp
V3 348 bp
V3 498 bp
E1
E1 E4 E5 E6 E7
E7E6
E4 E5 E6 E7
E2 E4 E5 E6 E7
E6 E7
Figure 2. Scheme of the variants of splicing of IL-15Ra from
Caco-2 cells. Five variants were obtained, two of them belong to
sequences of variants 1 and 2, while the remaining three
sequences belong to the sequence of variant 3. The variant of
276 bp isolated from variant 1 and 2, lacks exons 2 to 5; the
variant of 510 bp lacks exons 2 and 3. From the products derived
from the third variant (whose coding sequence initiated in the
second exon), the shortest one is only composed by a partial
zone of exon 6 and exon 7. The product of 348 bp lacks exons 2
and 3; and, finally, the longest of the products, 498 bp, contains
exon 2, although it lacks exon 3 and, partially, exon 4.
Table 2. Main features of predicted proteins.
Predicted isoforms
Variant Residue (aa) IP MM (kDa)
V1-2 276 bp 91 8.361 9.87
V1-2 510 bp 169 6.922 17.65
V3 130 bpa 14 11.048 1.49
V3 130 bpb 27 4.224 3.06
V3 348 bp 115 5.442 12.14
V3 498 bp 165 6.746 17.98
IP: isoelectric point; MM: molecular mass; V: variant. aPredicted protein
from the first ATG that appears in the sequence. bPredicted protein from
the second ATG that appears in the sequence.
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IL-15R isoforms in human epithelial cells
As IL-15Ra isoforms were described in Caco-2 cells,
epithelial cells from healthy individuals were obtained
by epithelial cell isolation and sorting to assess for IL-
15Ra isoforms in vivo (n¼ 7, ﬁve of which were from
colon and the remaining from duodenum). After spe-
ciﬁc PCR was performed for each of the IL-15Ra vari-
ants and isoforms, 348 and 130 bp isoforms (both of
them derived from variant 3) were present in almost
all epithelial samples (Figure 7). Other IL-15Ra iso-
forms were also present in epithelial cells from some
of the donors as the 510-bp isoform was present in
three of the samples; the 276-bp isoform was present
in one of the samples; and the 498-bp isoform was pre-
sent in two of the samples (Figure 7).
Discussion
Gene expression can be modulated diﬀerently in each
tissue according to the methylation of the DNA chain,
the modiﬁcation of histone or the level of packing,
among other factors.20 All these epigenetic modiﬁca-
tions are related to gene expression, as well as to the
presence of diﬀerent variants of splicing.21 This work is
focused on the intestinal epithelium as an essential
physical barrier and an immunological regulator in
the intestine.17 Deregulation of the physiological envir-
onment around this layer may contribute to the devel-
opment of autoimmune diseases such as celiac disease
or IBD.16,17,22
We have identiﬁed ﬁve new IL-15Ra isoforms, not
previously known, that co-exist in the intestinal epithe-
lial cells. Two of them were derived from variants 1 and
2; the remaining isoforms were derived from variant 3.
Although protein expression was conﬁrmed for most of
the IL-15Ra isoforms, none of them would be able to
bind IL-15 as they lack the sushi domain (exon 2).
Furthermore, none of the isoforms would follow the
secretory pathway, as they did not co-localize with
Golgi apparatus or lysosomal proteins, or showed a
variation on the predicted molecular mass that may
indicate a glycosylation process. As a result, their pro-
tein function is unclear. If these isoforms could be
translated in vivo, the resulting proteins may have
other signaling functions rather than being present in
the cell membrane and participating in an IL-15-depen-
dent signaling mechanism. Instead, these proteins
Figure 3. Alignment of the sequence of predicted protein of isoform containing 498 bp with the full sequence of IL-15Ra. The
sequence of each domain includes the following residues: the signal peptide 1–30, the sushi domain 31–95, the linker domain 96–127,
the proline-threonine rich domains 127–205, the transmembrane domain 206–229 and the cytoplasmic domain 230–267. The amino
acids that participate in IL-15 binding are marked with an arrow (glutamic acid and asparagine).
KDa
50.4
44.8
42.6
35.8
32.7
pEGFP
V1-2
276 bp
V1-2
510 bp
V3
130 bp
V3
348 bp
V3
498 bp
Figure 4. EGFP Western blot detection of transfected Caco-2
proteins. The approximate molecular mass is shown on the left
and it is expressed in kDa.
pEGFP: transfected cells with the empty vector; V: variant.
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might signal in alternative ways as all of them would
have the cytoplasmic domain (codiﬁed by exon 7),
which has been shown to participate in IL-15-indepen-
dent signaling in diﬀerent models.12,13
However, IL-15Ra isoform RNA could act by inter-
fering in the normal process of translation of full-length
IL-15Ra mRNA variants. In recent years, the compre-
hension of how genes are regulated is increasing as more
pEGFP V1-2 276 bp V1-2 510 bp V3 130 bp V3 348 bp
Negative
Calnexin
COPB
LAMP1
Figure 5. Immunofluorescence of transfected Caco-2 cells with pEGFP (control); isoforms containing 276 and 510 bp derived from
variants (V) 1 and 2; and isoforms containing 130 and 348 bp derived from variant 3. Cell nucleus are shown in blue, EGFP fused
proteins are shown in green and specific cell-compartment dyeing is shown in red. Calnexin was used to detect the endoplasmic
reticulum; COPB was used to detect the Golgi apparatus; and lysosomal membrane-associated protein 1 (LAMP-1) was used to detect
the lysosomes. Images were taken in a confocal Leica microscope (63 objective). The bars indicate a size of 10 mm.
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Figure 6. Expression of each isoform of IL-15Ra in cultured Caco-2 cells in presence of AZA for 48 h (n¼ 6). On the left side, the
relative quantification of IL-15Ra variants and isoforms is shown; on the right side, the semi-quantitative expression of shorter IL-15Ra
isoforms is shown. Median and interquartile range are represented. *P< 0.05, **P< 0.01. V: variant.
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players have been identiﬁed, such as microRNA,23 long
non-coding RNA or circular RNA.24,25 Indeed, process-
ing of full-length IL-15Ra mRNA into smaller isoforms
could act as a regulatory mechanism, as the availability
of the full-length copy is limited, therefore decreasing the
amount of IL-15Ra protein capable of binding IL-15
and signal through trans-presentation. Besides, these
novel IL-15Ra isoforms may play a role on IL-15Ra
mRNA stability, on nuclear–cytoplasm traﬃc, or as
microRNA precursors.
It has been previously described that the IL-15Ra
isoform lacking exon 2 is located in the endoplasmic
reticulum, the Golgi apparatus or the cytoplasmic ves-
icles;10 while isoforms lacking exon 3, exons 3 and 4, or
exons 3 to 5 are located in the endoplasmic reticulum
and/or the Golgi apparatus.26,27 The results described
in this paper are in agreement with these studies as the
ﬁve isoforms lack exon 2, 3 and, in some cases, exons 4
and 5, and they seem to be located in the cytoplasm
and, partially, in the endoplasmic reticulum.
Furthermore, the results showed that IL-15Ra is
regulated through methylation of DNA in Caco-2
cells as isoforms derived from variants 1 and 2
increased their expression in presence of AZA.
Apparently, variant 3 is diﬀerently aﬀected by the
methylation of DNA as not all the isoforms derived
from this variant increased their expression under the
same conditions, and it may indicate that variant 3 and
the 498-bp isoform are beneﬁted by the lack of DNA
methylation in comparison with other derived isoforms.
In general, these results are in agreement with previous
reports,15,28,29 suggesting that DNA methylation could
underlie an isoform switch in IL-15RA. Whether the
eﬀect of DNA methylation on IL-15Ra gene is due to
cis or trans methylation is not known as AZA acts as a
general inhibitor of de novo methylation; however,
Diniz et al. found evidence of regulation on a CpG
island located on the regulatory 5’ upstream region
and on the exon 1 of the IL-15Ra gene.15
Furthermore, diﬀerences in the regulation through
DNA methylation found between variant 3 and the
remaining isoforms agree with the diﬀerences on IL-
15Ra transcript sequences, as variant 3 sequence con-
tains an alternative exon 1. Finally, the presence of the
described isoforms was conﬁrmed in epithelial cells
from duodenal or colon biopsies from healthy individ-
uals, proving their expression in vivo.
The role of the IL-15/IL-15Ra signaling pathway is
crucial in autoimmune intestinal diseases, as well as in
colorectal cancer. In autoimmune conditions, such as
celiac disease and IBD, both IL-15 and IL-15Ra are
up-regulated in the intestinal mucosa of patients suﬀer-
ing from these diseases, and this is maintained in
patients with clinical remission.16,30 As a result, the pro-
portion of CD8+ T cells or intraepithelial lymphocytes
is increased and a chronic inﬂammation of the mucosa
is developed. In colorectal cancer, IL-15 can play a dual
role as a protective factor with anti-tumor eﬀects,31 and
a contributor to mucosal hyperplasia and angiogenesis,
resulting in tumor progression and metastasis.32
Interestingly, other alternative splicing variants from
cytokine receptors have already been associated to
IBD,33,34 and with human colon cancer IL-8 expres-
sion.35 Moreover, gene expression and alternative spli-
cing are not only dependent on the tissue, but also on
epigenetic factors,21 and changes in the expression of
intestinal genes have been found to be related to the
inhibition of histone deacetylation36 and an increased
DNA methylation,37 Several epigenetic mechanisms
have been found to be diﬀerently regulated in the intes-
tinal mucosa of patients with celiac disease, IBD and
colorectal cancer.38–40 Interestingly, the IL-15 gene is
hypomethylated in IBD.41
In summary, ﬁve novel isoforms of IL-15Ra have been
identiﬁed in human intestinal epithelial cells, which are
commonly distributed through the cytoplasmic and endo-
plasmic reticulum compartments. These isoforms cannot
bind IL-15 and their biological activity is unknown.
Moreover, IL-15Ra mRNA was conﬁrmed to be regu-
lated by methylation of DNA. Further studies may be
useful to clarify the pathogenesis of some intestinal dis-
eases, bearing in mind that factors such as diet, gender or
microbiota may aﬀect the epigenetics of the intestine.
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